CareDx (NASDAQ:CDNA) CFO Sells $166,271.13 in Stock

Key Points

  • CareDx Director Michael Goldberg sold 13,800 shares for about $1.09 million at an average price of $79.15 under a pre-arranged Rule 10b5-1 plan. He retained 48,526 shares after reducing his position by 22.14%.
  • CareDx reported quarterly EPS of $0.70, beating the $0.25 consensus, while revenue rose 39.3% year over year to $139.36 million—also above estimates.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $70.33. The stock opened at $73.72 and had a 12-month range of $15.15 to $90.87.

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) CFO Keith Kennedy sold 2,097 shares of the business's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $79.29, for a total value of $166,271.13. Following the transaction, the chief financial officer owned 199,147 shares in the company, valued at approximately $15,790,365.63. This represents a 1.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keith Kennedy also recently made the following trade(s):

  • On Thursday, November 5th, Keith Kennedy sold 61,961 shares of CareDx stock. The shares were sold at an average price of $77.82, for a total value of $4,821,805.02.

CareDx Price Performance

CDNA opened at $73.72 on Tuesday. CareDx, Inc. has a one year low of $15.15 and a one year high of $90.87. The business has a 50 day simple moving average of $66.80 and a two-hundred day simple moving average of $36.97. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 120.92 and a beta of 2.51.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million for the quarter, compared to analyst estimates of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The business's quarterly revenue was up 39.3% compared to the same quarter last year. During the same period last year, the company earned $0.03 EPS. As a group, sell-side analysts expect that CareDx, Inc. will post 1.00 EPS for the current fiscal year.

Institutional Trading of CareDx




Institutional investors and hedge funds have recently bought and sold shares of the stock. Nykredit A S bought a new stake in CareDx during the 2nd quarter valued at approximately $25,000. Integrated Wealth Concepts LLC purchased a new position in shares of CareDx during the 2nd quarter worth approximately $29,000. Reyes Financial Architecture Inc. purchased a new position in shares of CareDx during the 3rd quarter worth approximately $50,000. Signaturefd LLC purchased a new position in shares of CareDx during the 3rd quarter worth approximately $51,000. Finally, Global Retirement Partners LLC raised its position in shares of CareDx by 11,955.6% in the 3rd quarter. Global Retirement Partners LLC now owns 1,085 shares of the company's stock worth $71,000 after acquiring an additional 1,076 shares in the last quarter.

Analyst Ratings Changes

CDNA has been the subject of a number of recent analyst reports. BTIG Research upped their target price on CareDx from $81.00 to $92.00 and gave the company a "buy" rating in a report on Friday, October 30th. Weiss Ratings upgraded shares of CareDx from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Canaccord Genuity Group set a $99.00 price target on shares of CareDx in a report on Friday, October 30th. Piper Sandler initiated coverage on shares of CareDx in a research report on Wednesday, November 11th. They set an "overweight" rating and a $100.00 price objective on the stock. Finally, Wall Street Zen lowered shares of CareDx from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $70.33.

Read Our Latest Report on CareDx

CareDx Company Profile

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

See Also

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at CareDx?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for CareDx and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles